Importantly, as Amlexanox has already been administered to humans in a clinical trial for Type 2 diabetes (22), repurposing this drug in PC patients who are resistant to AR targeting therapies could be tested quickly. The gene discussed is AR; the disease is type 2 diabetes mellitus.